Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must have chronic genotype 1 HCV infection with HCV RNA level \>= 5.0 log10 IU/mL~* Patient has never received treatment for HCV~* Patient must be willing to use contraceptive measures from the time of informed consent to 6 months after last dose of study medication~Exclusion Criteria:~* Co-infection with any other HCV genotype or co-infection with the human immunodeficiency virus (HIV)~* Diagnosed with hepatic cirrhosis or hepatic failure~* A medical condition which is a contraindication to pegIFN or ribavirin therapy~* History of, or any current medical condition which could impact the safety of the patient in the study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- TMC435 100 mg 12 Wks + PR 24/48 (Type: EXPERIMENTAL): Participants received TMC435 100 mg once daily with PegIFNα-2a and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 24. Treatment was stopped at Week 24 for participants who achieved HCV RNA \< 1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable HCV RNA at Week 12. All other participants continued PR until Week 48.
- PBO 12 Wks + PR 48 (Type: EXPERIMENTAL): Participants received placebo (PBO) once daily with PegIFNα-2a and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 48.

Based on this trial design, predict the completion outcome and termination type (if applicable).